@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix nkg: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression.";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:has_population_context sub:cohort;
bl:provided_by ;
bl:publications ;
bl:relation nkg:OffLabelIndication .
sub:cohort rdfs:label "Adults";
bl:category bl:Cohort .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-7641-6446 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
npx:hasSignature "jibBjqxHwxwtJJLnMceo895jPhpjcsSoUNZNeKYMJOW4/dG+VPlrrMAd+b1hsSOKlRCNsgtjRMBzNNqH5h/G4mwMQVTKBX39usmXyxn5ACTxDvchhwzikAMZNAboiVlOfPMmQr603Gs4qxs+/gQiAxn7G9zvMQuJdT0wYOSUHlc=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-06-28T20:22:18.520+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-7641-6446;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}